Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-02
2007-01-02
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S269000, C544S295000, C544S316000
Reexamination Certificate
active
10897040
ABSTRACT:
The present invention relates to substituted dihydropyrimidine inhibitors of calcium channel function having formula Iwhere A, a, J, R1, R2R3, R4, and R5, are defined herein; pharmaceutical compositions comprising said compounds; and methods of treating calcium channel-dependent disorders, including hypertension.
REFERENCES:
patent: 4640922 (1987-02-01), Cho et al.
patent: 4683234 (1987-07-01), Cho et al.
patent: 4684655 (1987-08-01), Atwal
patent: 4684656 (1987-08-01), Atwal
patent: 4689414 (1987-08-01), Atwal
patent: 4728652 (1988-03-01), Atwal
patent: 4753946 (1988-06-01), Atwal et al.
patent: 4769371 (1988-09-01), Atwal
patent: 4772602 (1988-09-01), Cho et al.
patent: 4824831 (1989-04-01), Atwal
patent: 4855301 (1989-08-01), Atwal et al.
patent: 4920124 (1990-04-01), Cho et al.
patent: 5202330 (1993-04-01), Atwal et al.
patent: 5403847 (1995-04-01), Gluchowski et al.
patent: 5889016 (1999-03-01), Bruce et al.
patent: 5942517 (1999-08-01), Nagarathnam et al.
patent: 6172066 (2001-01-01), Nagarathnam et al.
patent: 6228861 (2001-05-01), Nagarathnam et al.
patent: 6245773 (2001-06-01), Wong et al.
patent: 6268369 (2001-07-01), Nagarathnam et al.
patent: 6274585 (2001-08-01), Cui et al.
patent: 2002/0010186 (2002-01-01), Wong et al.
patent: 2005/0043339 (2005-02-01), Murugesan et al.
patent: 3840380 (1989-06-01), None
patent: 0 204 317 (1986-12-01), None
patent: 0 157 219 (1988-01-01), None
patent: 0 254 119 (1988-01-01), None
patent: 0 162 208 (1989-11-01), None
patent: 0 236 902 (1990-12-01), None
patent: 0 237 347 (1991-06-01), None
patent: 0 280 227 (1992-01-01), None
patent: 0 195 374 (1992-07-01), None
patent: 0 545 845 (1996-02-01), None
patent: 60-214778 (1985-10-01), None
patent: 60-246376 (1985-12-01), None
patent: 60-255778 (1985-12-01), None
patent: 61-130276 (1986-06-01), None
patent: 62-5968 (1987-02-01), None
patent: 62-87574 (1987-04-01), None
patent: 63-208580 (1988-08-01), None
patent: 1-249756 (1989-10-01), None
patent: 11-35483 (1999-02-01), None
patent: WO 96/14846 (1996-05-01), None
patent: WO 97/17969 (1997-05-01), None
patent: WO 97/42956 (1997-11-01), None
patent: WO 98/33791 (1998-08-01), None
patent: WO 98/51311 (1998-11-01), None
patent: WO 99/23072 (1999-05-01), None
patent: WO 00/02455 (2000-01-01), None
patent: WO 00/15845 (2000-03-01), None
patent: WO 00/37026 (2000-06-01), None
patent: WO 00/59882 (2000-10-01), None
patent: WO 01/02561 (2001-01-01), None
patent: WO 01/19845 (2001-03-01), None
patent: WO 02/06245 (2002-01-01), None
patent: WO 02/078639 (2002-10-01), None
patent: WO 02/079149 (2002-10-01), None
patent: WO 02/079169 (2002-10-01), None
patent: WO 03/007953 (2003-01-01), None
West, Solid Solutions, Solid state chemistry and it's applications, Wiley, New York, pp. 358 and 365, 1988.
Vippagunta et al., Crystalline solids, Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26, 2001.
Putney, Jr. et al., Mechanisms of capaciative calcium entry, Journal of Cell Science, 114(12), pp. 2223-2229, 2001.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition , vol. 2, pp. 1992-1996, 1996.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Simone, Oncology: Inroduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Atwal, K.S. et al., “Dihydropyrimidine Calcium Channel Blockers 5: Bicyclic Dihydropyrimidines as Potent Mimics of Dihydropyridines”, Bioorganic & Medicinal Chemistry Letters, vol. 1, No. 6, pp. 291-294 (1991).
Atwal, K.S. et al., “Substituted 1,4-Dihydropyrimidines. 3. Synthesis of Selectively Functionalized 2-Hetero-1,4-dihydrpyrimidines”, J. Org. Chem., vol. 54, No. 25, pp. 5898-5907 (1989).
Baylis, C. et al., “Comparison of L-Type and Mixed L- and T-Type Calcium Channel Blockers on Kidney Injury Caused by Deoxycorticosterone-Salt Hypertension in Rats”, American Journal of Kidney Diseases, vol. 38, No. 6, pp. 1292-1297 (2001).
Atwal, K.S. et al., “Dihydropyrimidine Calcium Channel Blockers. 2. 3-Substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines”, J. Med. Chem., vol. 33, No. 9, pp. 2629-2635 (1990).
Atwal, K.S. et al., “Dihydropyrimidine Calcium Channel Blockers: 2-Heterosubstituted-4-Aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines”, J. Med. Chem., vol. 33, No. 5, pp. 1510-1515 (1990).
Atwal, K.S. et al., “Dihydropyrimidine Calcium Channel Blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Orally Effective Antihypertensive Agents”, J. Med. Chem., vol. 34, No. 2, pp. 806-811 (1991).
Bhattacharjee, A. et al., “T-Type Calcium Channels Facilitate Insulin Secretion by Enhancing General Excitability in the Insulin-Secreting β-Cell Line, INS-1”, Endocrinology, vol. 138, No. 9, pp. 3735-3740 (1997).
Bilici, D. et al., “Protective Effect of T-Type Calcium Channel Blocker in Histamine-Induced Paw Inflammation in Rat”, Pharmacological Research, vol. 44, No. 6, pp. 527-531 (2001).
Catterall, W.A. et al., “Structure and Regulation of Voltage-Gated Ca2+Channels”, Annu. Rev. Cell Dev. Biol., vol. 16, pp. 521-555 (2000).
Chemin, J. et al., “Specific contribution of human T-type calcium channel isotypes (α1G, α1Hand α1L) to neuronal excitability”, Journal of Physiology, vol. 540, Pt. 1, pp. 3-14 (2002).
Cho, H. et al., “Dihydropyrimidines: Novel Calcium Antagonists with Potent and Long-Lasting Vasodilative and Antihypertensive Activity”, J. Med. Chem., vol. 32, No. 10, pp. 2399-2406 (1989).
Cho, H. et al., “On the Tautomerism of Dihydropyrimidens: The Influence of the 2- and 5- Substituents on the Observation of Tautomers”, J. Am. Chem. Soc., vol. 110, No. 14, pp. 4832-4834 (1988).
Cho, H. et al., “Regioselective Synthesis ofN-Substituted Dihydropyrimidin-2(1H) or (3H)-one”, Tetrahedron Letters, vol. 29, No. 42, pp. 5405-5408 (1988).
Cho, H. et al., “Synthesis of 3-Substituted 3,4-Dihydropyrimidines:N-Alkoxy-Carbonylation with Trichloromethyl Chloroformate and Alcohols”, Heterocyles, vol. 27, No. 3, pp. 769-774 (1988).
Clozel, J.-P. et al., “Voltage-Gated T-Type Ca2+Channels and Heart Failure”, Proceedings of the Association of American Physicians, vol. 111, No. 5, pp. 429-437 (1999).
Dhar, T.G.M. et al., “Design and Synthesis of Novel α1aAdrenoceptor-Selective Antagonists. 2. Appraoches To Eliminate Opioid Agonist Metabolites via Modification of Linker and 4-Methoxycarbonyl-4-phenylpiperidine Moiety”, J. Med. Chem., vol. 42, No. 23, pp. 4778-4793 (1999).
Glasser, S.P., “The Relevance of T-Type Calcium Antagonists: A Profile of Mibefradil”, J. Clin. Pharmacol., vol. 38, pp. 659-669 (1998).
Harada, K. et al., “Clinical Efficacy of Efonidipine Hydrochloride, a T-type Calcium Channel Inhibitor, on Sympathetic Activites—Examination Using Spectral Analysis of Heart Rate/Blood Pressure Variabilities and123I-Metaiodobenzylguanidine Myocardial Scintigraphy”, Circulation Journal, vol. 67, pp. 139-145 (2003).
Hayashi, K. et al., “Effect of Efonidipine and ACE Inhibitors on Proteinuria in Human Hypertension With Renal Impairment”, American Journal of Hypertension, vol. 16, No. 2, pp. 116-122 (2003).
Honda, M. et al., “Divergent renal vasodilator action of L- and T-type calcium antagonistsin vivo”, Journal of Hypertension, vol. 19, No. 11, pp. 2031-2037 (2001).
Karam, H. et al., “Contrasting Effects of Selective T- and L-Type Calcium Channel Blockade on Glomerular Damage in DOCA Hypertensive Rats”, Hypertension, vol. 34, pp. 673-678 (1999).
Kochegarov, A.A., “Therapeutical application of voltage-gated calcium channel modulators”, Expert Opin. Ther. Patents, vol. 12, No. 2, pp. 243-287 (2002).
Lagu, B. et al., “Design and Syn
Bisacchi Gergory S.
Ewing William R.
Gu Zhengxiang
Murugesan Natesan
Bristol-Myers Squibb Co.
Duncan Laurelee A.
Rao Deepak
LandOfFree
Substituted dihydropyrimidine inhibitors of calcium channel... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted dihydropyrimidine inhibitors of calcium channel..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted dihydropyrimidine inhibitors of calcium channel... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3786097